Medartis Holding AG

Informe acción SWX:MED

Capitalización de mercado: CHF1.1b

Medartis Holding Dirección

Dirección controles de criterios 3/4

El CEO de Medartis Holding's es Christoph Bronnimann , nombrado en Sep 2019, tiene una permanencia de 4.58 años. compensación anual total es CHF1.87M, compuesta por 26.8% salario y 73.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.27% de las acciones de la empresa, por valor de CHF2.94M. La antigüedad media del equipo directivo y de la junta directiva es de 3.3 años y 3 años, respectivamente.

Información clave

Christoph Bronnimann

Chief Executive Officer (CEO)

CHF1.9m

Compensación total

Porcentaje del salario del CEO26.8%
Permanencia del CEO4.7yrs
Participación del CEO0.3%
Permanencia media de la dirección3.3yrs
Promedio de permanencia en la Junta Directiva3.1yrs

Actualizaciones recientes de la dirección

Shareholders Will Probably Not Have Any Issues With Medartis Holding AG's (VTX:MED) CEO Compensation

Apr 11
Shareholders Will Probably Not Have Any Issues With Medartis Holding AG's (VTX:MED) CEO Compensation

Recent updates

Shareholders Will Probably Not Have Any Issues With Medartis Holding AG's (VTX:MED) CEO Compensation

Apr 11
Shareholders Will Probably Not Have Any Issues With Medartis Holding AG's (VTX:MED) CEO Compensation

The Returns On Capital At Medartis Holding (VTX:MED) Don't Inspire Confidence

Feb 14
The Returns On Capital At Medartis Holding (VTX:MED) Don't Inspire Confidence

Medartis Holding (VTX:MED) Will Be Hoping To Turn Its Returns On Capital Around

Oct 24
Medartis Holding (VTX:MED) Will Be Hoping To Turn Its Returns On Capital Around

Is Medartis Holding (VTX:MED) A Risky Investment?

Oct 03
Is Medartis Holding (VTX:MED) A Risky Investment?

Is Medartis Holding AG (VTX:MED) Expensive For A Reason? A Look At Its Intrinsic Value

Sep 06
Is Medartis Holding AG (VTX:MED) Expensive For A Reason? A Look At Its Intrinsic Value

Market Still Lacking Some Conviction On Medartis Holding AG (VTX:MED)

Jun 21
Market Still Lacking Some Conviction On Medartis Holding AG (VTX:MED)

Medartis Holding (VTX:MED) May Have Issues Allocating Its Capital

Jan 31
Medartis Holding (VTX:MED) May Have Issues Allocating Its Capital

Why Medartis Holding AG (VTX:MED) Could Be Worth Watching

Oct 30
Why Medartis Holding AG (VTX:MED) Could Be Worth Watching

These Analysts Think Medartis Holding AG's (VTX:MED) Sales Are Under Threat

Sep 07
These Analysts Think Medartis Holding AG's (VTX:MED) Sales Are Under Threat

When Should You Buy Medartis Holding AG (VTX:MED)?

Jul 29
When Should You Buy Medartis Holding AG (VTX:MED)?

Medartis Holding (VTX:MED) Could Be Struggling To Allocate Capital

May 06
Medartis Holding (VTX:MED) Could Be Struggling To Allocate Capital

At CHF123, Is It Time To Put Medartis Holding AG (VTX:MED) On Your Watch List?

Feb 08
At CHF123, Is It Time To Put Medartis Holding AG (VTX:MED) On Your Watch List?

Medartis Holding (VTX:MED) Will Be Hoping To Turn Its Returns On Capital Around

Jan 18
Medartis Holding (VTX:MED) Will Be Hoping To Turn Its Returns On Capital Around

We Think Medartis Holding (VTX:MED) Can Stay On Top Of Its Debt

Nov 10
We Think Medartis Holding (VTX:MED) Can Stay On Top Of Its Debt

Medartis Holding (VTX:MED) Could Be Struggling To Allocate Capital

Sep 29
Medartis Holding (VTX:MED) Could Be Struggling To Allocate Capital

Some Investors May Be Worried About Medartis Holding's (VTX:MED) Returns On Capital

Jun 08
Some Investors May Be Worried About Medartis Holding's (VTX:MED) Returns On Capital

How Much Of Medartis Holding AG (VTX:MED) Do Insiders Own?

Mar 16
How Much Of Medartis Holding AG (VTX:MED) Do Insiders Own?

We're Watching These Trends At Medartis Holding (VTX:MED)

Feb 09
We're Watching These Trends At Medartis Holding (VTX:MED)

Medartis Holding (VTX:MED) Shareholders Have Enjoyed A 10% Share Price Gain

Jan 04
Medartis Holding (VTX:MED) Shareholders Have Enjoyed A 10% Share Price Gain

What Type Of Shareholders Own The Most Number of Medartis Holding AG (VTX:MED) Shares?

Nov 19
What Type Of Shareholders Own The Most Number of Medartis Holding AG (VTX:MED) Shares?

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Christoph Bronnimann en comparación con los beneficios de Medartis Holding?
FechaCompensación totalSalarioIngresos de la empresa
Dec 31 2023CHF2mCHF500k

CHF619k

Sep 30 2023n/an/a

-CHF3m

Jun 30 2023n/an/a

-CHF7m

Mar 31 2023n/an/a

-CHF6m

Dec 31 2022CHF2mCHF500k

-CHF6m

Sep 30 2022n/an/a

-CHF3m

Jun 30 2022n/an/a

-CHF241k

Mar 31 2022n/an/a

CHF3m

Dec 31 2021CHF3mCHF500k

CHF7m

Sep 30 2021n/an/a

CHF9m

Jun 30 2021n/an/a

CHF12m

Mar 31 2021n/an/a

CHF6m

Dec 31 2020CHF2mCHF467k

-CHF944k

Sep 30 2020n/an/a

-CHF3m

Jun 30 2020n/an/a

-CHF4m

Mar 31 2020n/an/a

-CHF1m

Dec 31 2019CHF782kCHF168k

CHF2m

Compensación vs. Mercado: La compensación total de Christoph($USD2.05M) está por encima de la media de empresas de tamaño similar en el mercado Swiss ($USD1.35M).

Compensación vs. Ingresos: La compensación de Christoph ha sido consistente con los resultados de la empresa en el último año.


CEO

Christoph Bronnimann (57 yo)

4.7yrs

Permanencia

CHF1,866,937

Compensación

Dr. Christoph Bronnimann is Chief Executive Officer at Medartis AG since September 2019. He has been the Chief Executive Officer and Member of Executive Management Board at Medartis Holding AG since Septem...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Christoph Bronnimann
CEO & Member of Executive Management Board4.7yrsCHF1.87m0.27%
CHF 2.9m
Thomas Straumann
Founder & Vice Chairman26.3yrsCHF291.97k41.48%
CHF 451.1m
Dirk Kirsten
CFO & Member of the Executive Management Board3.2yrssin datos0.029%
CHF 318.5k
Mareike Loch
VP of EMEA & Member of Executive Management Board3.8yrssin datos0.054%
CHF 582.6k
Manuel Schaer
CTO & Member of the Executive Board3.5yrssin datos0.017%
CHF 185.0k
Mario Casa
COO & Member of Management Board2.3yrssin datos0.0027%
CHF 29.1k
Inge Maes
Chief Human Resources Officer & Executive Management Board Memberno datasin datossin datos
Fabian Hildbrand
Head of Corporate Communicationsno datasin datossin datos
Anisha Wharton
Head of Regulatory Affairs3.2yrssin datossin datos

3.3yrs

Permanencia media

54yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de MED se considera experimentado (3.3 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Thomas Straumann
Founder & Vice Chairman26.3yrsCHF291.97k41.48%
CHF 451.1m
Damien Tappy
Independent Non-Executive Director6.3yrsCHF188.29k0.19%
CHF 2.0m
Marco Gadola
Independent Chairman4.1yrsCHF568.06k0.065%
CHF 709.0k
Ciro Roemer
Independent Director2.1yrsCHF112.76k0.0097%
CHF 104.9k
Willi Miesch
Independent Non Executive Director14.3yrsCHF161.68k0%
CHF 0
Martha Shadan
Independent Non-Executive Directorless than a yearsin datossin datos
Jennifer Dean
Independent Non-Executive Directorless than a yearsin datossin datos
Nadia Schmidt
Independent Director2.1yrsCHF171.53k0.0072%
CHF 78.7k

3.1yrs

Permanencia media

59.5yo

Promedio de edad

Junta con experiencia: La junta directiva de MED se considera experimentada (3 años de antigüedad promedio).